Skip to content
TrialScanner

NCT05614063

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

Phase 3CompletedXENELead

Registry record

Lead sponsor
Xenon Pharmaceuticals Inc.
Conditions
Focal Onset Seizures
Primary completion
Jan 12, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05614063 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.